痴呆前认知表型影响阿尔茨海默病血液生物标志物解读
两项法国多中心前瞻性队列(MEMENTO和BALTAZAR)纳入无痴呆参与者,评估血液p-tau217预测脑淀粉样变性的诊断性能是否随认知表型(SCI、cAD-MCI、uAD-MCI)而变化。结果显示脑淀粉样变性患病率及p-tau217模型的AUC、PPV在不同表型间存在差异,NPV均较高;作者认为临床使用血液 biomarkers 时应结合详细认知表型以避免假阳性误诊。
要点
- 无痴呆人群中,脑淀粉样变性患病率在SCI为16.5%、cAD-MCI为45.9%、uAD-MCI为24.5%。
- p-tau217模型预测脑淀粉样变性的AUC在SCI为0.78、cAD-MCI为0.91、uAD-MCI为0.87。
- 外部切点下PPV在SCI为60.0%、cAD-MCI为90.0%、uAD-MCI为74.5%,NPV为84.2%-90.2%。
核心结论
- 在无痴呆患者中,脑淀粉样变性患病率随认知表型而异,并与血液p-tau217模型预测脑淀粉样变性的诊断性能相关。
- 临床实践中使用血液生物标志物时应结合超出SCI、MCI或痴呆基本分类的详细认知表型,以避免假阳性导致的误诊。
研究设计与样本
- 研究设计包含两项观察性前瞻性队列研究:MEMENTO队列(2011-2014年入组,随访5年)和BALTAZAR队列(2010-2015年入组,随访3年),均为法国记忆门诊的多中心队列。
- 分析纳入无痴呆且具有基线血p-tau217测量和已知淀粉样状态(通过脑脊液Aβ42/Aβ40比值或PET确定)的参与者:MEMENTO队列776例(总2323例),BALTAZAR队列193例(总1040例)。
- 参与者认知表型分为主观认知障碍(SCI)、常见AD表型的MCI(cAD-MCI:海马型遗忘综合征、后皮质萎缩或logopenic原发性进行性失语)以及不常见AD或其他表型的MCI(uAD-MCI)。
主要发现
- MEMENTO队列(中位年龄71岁,女性57%)中,脑淀粉样变性患病率在SCI为16.5%(20/121)、cAD-MCI为45.9%(78/170)、uAD-MCI为24.5%(119/485)。
- p-tau217模型预测脑淀粉样变性的AUC在SCI为0.78(95%CI 0.66-0.89)、cAD-MCI为0.91(95%CI 0.86-0.95)、uAD-MCI为0.87(95%CI 0.84-0.91)。
- 外部切点下PPV在SCI为60.0%、cAD-MCI为90.0%、uAD-MCI为74.5%;NPV范围为84.2%至90.2%。
- 内部开发切点下PPV在SCI为52.6%、cAD-MCI为84.0%、uAD-MCI为72.3%;所有亚组NPV均高(91.7%-94.6%)。
- 在cAD-MCI亚组中, incident dementia 发生率随脑淀粉样变性概率强烈增加;BALTAZAR队列重复分析结果相似。
关键数值与推荐
- 使用已发表和内部开发的切点,均设定90%灵敏度和特异度。
- 脑淀粉样变性概率通过包含年龄、性别和APOE基因型的p-tau217逻辑回归得出。
临床怎么用
- 在无痴呆患者中解读血p-tau217结果时,应考虑详细认知表型,因不同表型下脑淀粉样变性患病率和诊断性能存在差异。
- 临床使用血液生物标志物时应结合超出SCI、MCI或痴呆基本分类的全面认知表型评估,以避免假阳性导致的误诊。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Blood phosphorylated tau 217 (p-tau217) showed good performance in predicting brain amyloidosis. However, the importance of detailed cognitive phenotyping in patients without dementia when interpreting p-tau217 results remains unclear. OBJECTIVE: To assess whether accuracy, negative predictive value (NPV), and positive predictive value (PPV) in predicting brain amyloidosis using p-tau217 varies across clinical presentations in patients without dementia. DESIGN, SETTING, AND PARTICIPANTS: The study design included 2 observational, prospective cohort studies: The Cohort of Outpatients From French Research Memory Centers in Order to Improve Knowledge on Alzheimer's Disease and Related Disorders (MEMENTO), with enrollment from 2011 to 2014 and 5 years of follow-up, and the Biomarker of Amyloid Peptide and Alzheimer's Disease Risk (BALTAZAR) cohort study, with enrollment from 2010 to 2015 and 3 years of follow-up. Both are multicenter cohorts conducted in French memory clinics. Participants without dementia were included for analysis if they had baseline blood p-tau217 measurement and a known amyloid status through cerebrospinal fluid amyloid β (Aβ)-42/Aβ-40 ratio or positron emission tomography. They presented with either subjective cognitive impairment (SCI), mild cognitive impairment (MCI) with a common Alzheimer disease (AD) phenotype (cAD-MCI: amnestic syndrome of hippocampal type, posterior cortical atrophy, or logopenic primary progressive aphasia), or MCI with uncommon AD or other phenotypes (uAD-MCI). Data were analyzed from May to September 2024. EXPOSURES: Blood p-tau217 concentrations. MAIN OUTCOMES AND MEASURES: Brain amyloidosis probabilities were derived from p-tau217 logistic regressions including age, gender, and APOE genotype. Published and internally developed cut points with 90% sensitivity and specificity were used. RESULTS: A total of 776 participants from the MEMENTO cohort (N = 2323 participants) and 193 participants from the BALTAZAR cohort (N = 1040) were included in this analysis. In the MEMENTO cohort (median [IQR] age, 71 [65-76] years; 444 female [57%]), brain amyloidosis prevalence was 16.5% (20 of 121) in SCI, 45.9% (78 of 170) in cAD-MCI, and 24.5% (119 of 485) in uAD-MCI. Area under the receiver operating characteristic curve for predicting brain amyloidosis with p-tau217 models was 0.78 (95% CI, 0.66-0.89), 0.91 (95% CI, 0.86-0.95), and 0.87 (95% CI, 0.84-0.91) in the SCI, cAD-MCI, and uAD-MCI subgroups, respectively. External cut points resulted in a PPV of 60.0%, 90.0%, and 74.5% in the SCI, cAD-MCI, and uAD-MCI subgroups, respectively. NPV ranged from 84.2% to 90.2%. With internally developed cut points, PPVs were 52.6%, 84.0%, and 72.3% in the SCI, cAD-MCI, and uAD-MCI subgroups, respectively. NPVs were high (91.7%-94.6%) in all subgroups. Rates of incident dementia strongly increased with the probability of brain amyloidosis in the cAD-MCI subgroup. Replicated analyses in the BALTAZAR cohort provided similar results. CONCLUSIONS AND RELEVANCE: Results from 2 clinical cohorts suggest that amyloid prevalence varied across cognitive phenotypes and was associated with the diagnostic performance of blood p-tau217 models to determine brain amyloidosis. Comprehensive cognitive phenotyping beyond the basic characterization of SCI, MCI, or dementia should accompany the use of blood biomarkers in clinical practice to avoid misdiagnosis due to false positives.
引用
- Bouteloup V, Villain N, Vidal JS, et al. Cognitive Phenotyping and Interpretation of Alzheimer Blood Biomarkers. JAMA Neurol. 2025. PMID: 40181683. doi:10.1001/jamaneurol.2025.0142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。